Vaccines against respiratory syncytial virus: The time has finally come

详细信息    查看全文

• 作者：Barney S. Graham ; ^{bgraham@nih.gov" class="auth_mail" title="E-mail the corresponding author}
• 关键词：RSV ; Immunization ; Vaccination ; Structure-based vaccine design ; Fusion ; Neutralization ; Vaccine-enhanced illness ; Bronchiolitis ; Pneumonia ; Infants ; Elderly ; Th2 ; Eosinophilia ; Subunit vaccine ; Vaccine vector ; Wheezing ; Asthma ; Protein conformation ; Epitope
• 刊名：Vaccine
• 出版年：2016
• 出版时间：24 June 2016
• 年：2016
• 卷：34
• 期：30
• 页码：3535-3541
• 全文大小：1055 K

文摘

Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality.